Abstract: The present invention is directed to .omega.-conotoxin peptides having 24-30 amino acids, six cysteines which form disulfide bonds between the first and fourth, second and fifth, and third and sixth cysteines, respectively, and an internal sequence of Cys-Arg-Lys-Thr-Xaa.sub.1 -Tyr-Xaa.sub.2 -Cys-Cys-Ser-Gly-Ser-Cys (SEQ ID NO:1). The invention is further directed to .omega.-conotoxin peptides of the generic formula Cys-Xaa.sub.1 -Gly-Xaa.sub.2 -Gly-Ala-Xaa.sub.3 -Cys-Arg-Lys-Thr-Xaa.sub.4 -Tyr-Xaa.sub.5 -Cys-Cys-Ser-Gly-Ser-Cys-Xaa.sub.6 -Arg-Gly-Xaa.sub.7 -Cys (SEQ ID NO:2). Preferably, the C-terminus is amidated. These peptides also contain three disulfide bonds. Examples of .omega.-conotoxin peptides within the generic formula are MVIIC having the formula Cys-Cys-Gly-Lys-Gly-Ala-Xaa.sub.1 -Cys-Arg-Lys-Thr-Xaa.sub.2 -Tyr-Asp-Cys-Cys-Ser-Gly-Ser-Cys-Gly-Arg-Arg-Gly-Lys-Cys (SEQ ID NO:3), wherein Xaa is preferably Pro or Hyp (4-hydroxyproline) and Xaa.sub.
Type:
Grant
Filed:
July 16, 1993
Date of Patent:
January 7, 1997
Assignee:
The University of Utah
Inventors:
Baldomero M. Olivera, David R. Hillyard, Julita S. Imperial, Virginia D. Monje
Abstract: The present disclosure relates to methods and compositions for modulating the action of G proteins. G proteins are important to cellular regulation in all human cells and their function is involved in a wide variety of human disease processes. In particular aspects, the present disclosure concerns the development of mastoparan analogs as well as other amphipathic and cationic peptides, termed receptor-based analogues, that can promote activation of one or more G proteins, and are therefore proposed to be useful in the treatment of a variety of disorders including asthma, ulcers, cardiovascular diseases and even Parkinson's disease.
Type:
Grant
Filed:
April 22, 1994
Date of Patent:
December 31, 1996
Assignee:
Board of Regents, The University of Texas
Abstract: The present invention provides peptides capable of stimulating neutrophils. In particular, the peptides prime neutrophils for a respiratory burst following treatment with N-formyl-L-methionyl-L-leucyl-Lphenylalanine. The peptides have an amino acid sequence substantially corresponding to amino acids 54 to 94 of FIG. 1 or a part thereof. These peptides may also be used in the treatment of a subject having depressed neutrophil function.
Abstract: Antibiotically and/or antimalarially active D-peptides of naturally occurring antibiotics such as cecropin A, B and D, melittin, and Magainin I and II and their addition, deletion and replacement analogs including homologous and heterologous analogs thereof.
Type:
Grant
Filed:
September 16, 1994
Date of Patent:
December 17, 1996
Assignee:
The Rockefeller University
Inventors:
Robert B. Merrifield, David Wade, Hans G. Boman
Abstract: Peptide derivatives with inhibitory activity on the enzyme systems involved in the oxidative burst of human phagocytic cells comprise a certain sequence of a number of carboxyl-terminal amino acids of human cytochrome b.sub.558. The derivatives may be used in medicaments for the treatment of inflammatory diseases.
Type:
Grant
Filed:
March 31, 1989
Date of Patent:
December 17, 1996
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Harry L. Malech, Karen J. Lomax, Daniel Rotrosen, Hiroyuki Nunoi
Abstract: Peptides, the C-terminal amides thereof and the pharmaceutically acceptable salts of the said peptides and amides are useful in the prevention and treatment of pain.
Type:
Grant
Filed:
October 27, 1994
Date of Patent:
December 3, 1996
Assignee:
British Technology Group Limited
Inventors:
Sergio H. Ferreira, Adrian F. Bristow, Stephen Poole
Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
Type:
Grant
Filed:
January 31, 1995
Date of Patent:
December 3, 1996
Assignee:
Eli Lilly and Company
Inventors:
Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, James E. Shields, David L. Smiley
Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
Type:
Grant
Filed:
January 31, 1995
Date of Patent:
November 12, 1996
Assignee:
Eli Lilly and Company
Inventors:
Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, James E. Shields, David L. Smiley
Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
Type:
Grant
Filed:
January 31, 1995
Date of Patent:
October 29, 1996
Assignee:
Eli Lilly and Company
Inventors:
Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffman, James E. Shields, David L. Smiley
Abstract: A polypeptide compound having antifungal activities of the following general formula: ##STR1## wherein R.sup.1 is hydrogen R.sup.2 is acyl group,R.sup.3 is hydroxy or acyloxy,R.sup.4 is hydroxy or hydroxysulfonyloxy,R.sup.4 is hydrogen or lower alkyl which may have one or more suitable substituent(s), andR.sup.6 is hydrogen, hydroxy or acyl (lower) alkylthio and a pharmaceutically acceptable salt thereof.
Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
Type:
Grant
Filed:
February 6, 1995
Date of Patent:
October 29, 1996
Assignee:
Eli Lilly and Company
Inventors:
Margret B. Basinski, Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, Brigitte E. Schoner, James E. Shields, David L. Smiley
Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
Type:
Grant
Filed:
February 6, 1995
Date of Patent:
October 22, 1996
Assignee:
Eli Lilly and Company
Inventors:
Margret Basinski, Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, Brigitte E. Schoner, James E. Shields, David L. Smiley
Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
Type:
Grant
Filed:
January 31, 1995
Date of Patent:
October 22, 1996
Assignee:
Eli Lilly and Company
Inventors:
Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, James E. Shields, David L. Smiley
Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
Type:
Grant
Filed:
January 31, 1995
Date of Patent:
October 8, 1996
Assignee:
Eli Lilly and Company
Inventors:
Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, James E. Shields, David L. Smiley
Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
Type:
Grant
Filed:
January 31, 1995
Date of Patent:
October 8, 1996
Assignee:
Eli Lilly and Company
Inventors:
Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, James E. Shields, David L. Smiley
Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
Type:
Grant
Filed:
January 31, 1995
Date of Patent:
October 8, 1996
Assignee:
Eli Lilly and Company
Inventors:
Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, James E. Shields, David L. Smiley
Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
Type:
Grant
Filed:
February 6, 1995
Date of Patent:
September 24, 1996
Assignee:
Eli Lilly and Company
Inventors:
Margret B. Basinski, Richard D. DiMarchi, William F. Heath, Jr., Brigitte E. Schoner
Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
Type:
Grant
Filed:
February 6, 1995
Date of Patent:
September 10, 1996
Assignee:
Eli Lilly and Company
Inventors:
Margret B. Basinski, Richard D. DiMarchi, William F. Heath, Jr., Brigitte E. Schoner
Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
Type:
Grant
Filed:
February 6, 1995
Date of Patent:
September 3, 1996
Assignee:
Eli Lilly and Company
Inventors:
Margret B. Basinski, Richard D. DiMarchi, William F. Heath, Jr., Brigitte E. Schoner
Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
Type:
Grant
Filed:
January 31, 1995
Date of Patent:
September 3, 1996
Assignee:
Eli Lilly and Company
Inventors:
Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, James E. Shields, David L. Smiley